• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Bionano Genomics Appoints Helene Klein as its First Ever Chief People Officer

    2/14/22 8:00:00 AM ET
    $BNGO
    $BODY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Industrial Machinery/Components
    Industrials
    Get the next $BNGO alert in real time by email

    SAN DIEGO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solution for visualization, interpretation and reporting of genomic data, today announced that it has appointed Helene Klein as its chief people officer, further strengthening its leadership team. As the company expands, culture and employee experience become key success factors. The appointment of a chief people officer today reflects Bionano's focus on maintaining and evolving its culture of innovative, disciplined, and rapid response to market needs.

    Ms. Klein was formerly the chief people officer at the Beachbody Company (NYSE:BODY) where she led the people function for 14 years. During her time there as CPO, the Beachbody employee population scaled from 150 employees to over 1100 in three countries, revenue grew from $150M to over $1B annually, and the company went public on the New York Stock Exchange. Prior to Beachbody, Ms. Klein held senior leadership roles in human resources in multiple global companies and industries, including healthcare, retail and consumer products.

    In this new position, Ms. Klein will be responsible for leading human resources, employer branding, and Bionano's diversity, equity and inclusion program. She will also be responsible for all aspects of Bionano's employee experience, including attracting, engaging, and retaining talent to support Bionano's continued growth.

    "I am pleased to welcome Helene to Bionano and thank her for embracing our why, which is to elevate human health and wellness by transforming the way the world sees the genome," commented Erik Holmlin, PhD, president and chief executive officer of Bionano Genomics. "Her breadth of experience and track record, especially at Beachbody, make her well-suited for creating one of the best employee experiences in the industry. All of us on the senior leadership team are really looking forward to partnering with Helene to amplify the incredible capabilities of our people and propel us to reach new heights."

    About Bionano Genomics

    Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company's mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit bionanogenomics.com, lineagen.com or biodiscovery.com

    Forward-Looking Statements of Bionano Genomics

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the impacts of Ms. Klein's hiring on Bionano's workforce. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; hiring efforts may not achieve the desired results; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2020 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

    CONTACTS

    Company Contact:

    Erik Holmlin, CEO

    Bionano Genomics, Inc.

    +1 (858) 888-7610

    [email protected]

    Investor Relations:

    Amy Conrad

    Juniper Point

    +1 (858) 366-3243

    [email protected]

     



    Primary Logo

    Get the next $BNGO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BNGO
    $BODY

    CompanyDatePrice TargetRatingAnalyst
    Bionano Genomics Inc.
    $BNGO
    11/15/2024Buy → Neutral
    Ladenburg Thalmann
    Bionano Genomics Inc.
    $BNGO
    9/10/2024Buy → Neutral
    BTIG Research
    Bionano Genomics Inc.
    $BNGO
    1/5/2023$4.00Sector Outperform
    Scotiabank
    Bionano Genomics Inc.
    $BNGO
    12/12/2022$3.50Buy
    BTIG Research
    Bionano Genomics Inc.
    $BNGO
    7/18/2022$12.00Outperform
    Oppenheimer
    The Beachbody Company Inc.
    $BODY
    5/5/2022$2.27Neutral
    Credit Suisse
    The Beachbody Company Inc.
    $BODY
    3/29/2022$2.40Neutral
    BofA Securities
    The Beachbody Company Inc.
    $BODY
    3/4/2022$6.25 → $4.75Buy
    DA Davidson
    More analyst ratings

    $BNGO
    $BODY
    Financials

    Live finance-specific insights

    See more
    • Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025

      SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, May 14th, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click hereWebcast Link:https://edge.media-server.com/mmc/p/vncjmqc9 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at https://ir.b

      5/7/25 4:01:00 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano to Report Fourth Quarter and Full Year 2024 Financial Results and Host a Conference Call Webcast on March 31, 2025

      SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Monday, March 31, 2025, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and full year 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Monday, March 31st, 2025Time:4:30 p.m. ETParticipant Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/5v2s5x5r Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website

      3/14/25 8:00:00 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano to Report Third Quarter 2024 Financial Results and Host a Conference Call and Webcast on November 13, 2024

      SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 13, 2024, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2024 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Wednesday, November 13th, 2024Time:4:30 p.m. ETParticipant Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/dmabxin9 Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on Bionano's investor relations website at h

      11/7/24 4:01:00 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BNGO
    $BODY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by The Beachbody Company Inc. (Amendment)

      SC 13D/A - Beachbody Company, Inc. (0001826889) (Subject)

      3/4/24 4:02:26 PM ET
      $BODY
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13D/A filed by The Beachbody Company Inc. (Amendment)

      SC 13D/A - Beachbody Company, Inc. (0001826889) (Subject)

      3/1/24 5:08:50 PM ET
      $BODY
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13D/A filed by The Beachbody Company Inc. (Amendment)

      SC 13D/A - Beachbody Company, Inc. (0001826889) (Subject)

      2/28/24 5:01:01 PM ET
      $BODY
      Industrial Machinery/Components
      Industrials

    $BNGO
    $BODY
    SEC Filings

    See more
    • SEC Form 10-Q filed by Bionano Genomics Inc.

      10-Q - Bionano Genomics, Inc. (0001411690) (Filer)

      5/14/25 4:11:22 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Bionano Genomics, Inc. (0001411690) (Filer)

      5/14/25 4:09:51 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Bionano Genomics Inc.

      DEFA14A - Bionano Genomics, Inc. (0001411690) (Filer)

      4/28/25 4:17:17 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BNGO
    $BODY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by General Counsel Dixon Jonathan V.

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      3/18/25 6:45:55 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Principal Accounting Officer Adamchak Mark

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      3/18/25 6:45:45 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President and CEO Holmlin R. Erik covered exercise/tax liability with 198 shares, decreasing direct ownership by 10% to 1,783 units (SEC Form 4)

      4 - Bionano Genomics, Inc. (0001411690) (Issuer)

      3/18/25 6:45:35 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BNGO
    $BODY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bionano Genomics downgraded by Ladenburg Thalmann

      Ladenburg Thalmann downgraded Bionano Genomics from Buy to Neutral

      11/15/24 7:40:01 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano Genomics downgraded by BTIG Research

      BTIG Research downgraded Bionano Genomics from Buy to Neutral

      9/10/24 7:37:53 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Scotiabank initiated coverage on Bionano Genomics with a new price target

      Scotiabank initiated coverage of Bionano Genomics with a rating of Sector Outperform and set a new price target of $4.00

      1/5/23 7:29:54 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BNGO
    $BODY
    Leadership Updates

    Live Leadership Updates

    See more
    • LeddarTech Appoints Chris Stewart as Chief Financial Officer

      QUEBEC CITY, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- LeddarTech®, an automotive software company that provides patented disruptive low-level sensor fusion and perception software technology for ADAS and AD, proudly announces the appointment of Mr. Chris Stewart as Chief Financial Officer ("CFO"). As CFO at LeddarTech, Mr. Stewart will be instrumental in supporting LeddarTech in completing its recently announced business combination with Prospector Capital Corp. and transitioning to a publicly traded company. Mr. Stewart has over 20 years of financial management experience at companies ranging from startups to large public companies. Mr. Stewart previously served as the Chief Financial

      11/15/23 12:07:00 AM ET
      $BNGO
      $PRSR
      $TSLA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Blank Checks
      Finance
    • Bionano Announces CFO Transition and Appointment of Gülsen Kama as Chief Financial Officer

      SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory role. Ms. Kama has an extensive background in business planning and execution, especially in operating environments that demand rigorous management of expenses to enable profitable growth. She was most recently Chief Financial Officer at Northern Data AG, where she created and implemented a global finance organization to enable strong growth. Prior to Northe

      8/14/23 8:00:00 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • The Beachbody Company, Inc. Announces Hiring of Mark R. Goldston To The Newly Created Role of Executive Chairman To Drive Transformation and Maximize Profitability

      The Beachbody Company, Inc. (NYSE:BODY) ("BODi" or the "Company"), a leading subscription health and wellness company, is thrilled to announce the appointment of Mark R. Goldston to the newly formed role of Executive Chairman of BODi's Board of Directors (the "Board"), effective June 15, 2023. In this strategic role, Mr. Goldston will be instrumental in partnering with the company's co-founder and CEO Carl Daikeler in guiding the Company's transformation, driving profitability, and leveraging its remarkable assets to unlock opportunities for growth. The appointment of Mr. Goldston marks an important milestone for BODi. With a proven track record as a turnaround expert, Mr. Goldston brings

      6/15/23 4:05:00 PM ET
      $BODY
      Industrial Machinery/Components
      Industrials

    $BNGO
    $BODY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bionano Laboratories Announces a Second Category I CPT Code for OGM Established by the AMA; this one for Use in Whole Genome Analysis for Constitutional Genetic Disorders

      SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASDAQ:BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced that the editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to constitutional genetic disorders. The CPT code is a key component in obtaining reimbursement for the OGM-Dx™ Postnatal Whole Genome SV and OGM-Dx™ Prenatal Whole Genome SV LDTs from third party pay

      5/19/25 8:00:00 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress

      SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today reported financial results for the first quarter ended March 31, 2025. "The first quarter of 2025 represents the first full quarter of execution after shifting strategy towards a focus on our base of routine users of optical genome mapping (OGM) and VIA™ software as the primary drivers of our revenue and gross profit.   We are pleased to see consistent utilization of our OGM systems and software combined with a year-over-year growth in consumables purchased by our customers we consider to be routine users of OGM. After significant reductions in costs and cash burn, together with our gross margin improve

      5/14/25 4:01:00 PM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bionano Laboratories Announces Publication of the Largest Study To-Date Evaluating Clinical Utility of Optical Genome Mapping Across Multiple Hematologic Malignancies

      In 58% or 303 of 519 cases, optical genome mapping (OGM) revealed somatic aberrations that were not detected by the standard cytogenetic workup (SCGW), including Tier 1, Tier 2 and Tier 3 structural variants (SVs) and copy number variants (CNVs)In 15% or 75 of 519 cases, OGM identified additional Tier 1 variants with detection rates varying by disease type, ranging from 52% in T-ALL to 0% in MPN. Every Tier 1 SV or CNV detected by OGM had direct diagnostic, prognostic, or therapeutic significance, meaning that the detection would provide additional clinical utility SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (NASD

      5/13/25 8:00:00 AM ET
      $BNGO
      Biotechnology: Laboratory Analytical Instruments
      Industrials